<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974297</url>
  </required_header>
  <id_info>
    <org_study_id>AVOCADO</org_study_id>
    <nct_id>NCT01974297</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid</brief_title>
  <acronym>AVOCADO</acronym>
  <official_title>Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sang Hak Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare combination atorvastatin/fenofibric acid 10/135mg
      with atorvastatin 20mg monotherapy in the mixed hyperlipidemia who were not at lipid goals
      with atorvastatin 10mg monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study conduct according to the standard operating procedure

        -  The sponsor, the investigator, and all other persons involved in the study at the study
           center or other facilities should conduct the study in accordance with the study
           protocol, each standard operating procedure, and Korea Good Clinical Pratice.

      Data quality control

        -  In order to ensure the reliability of all study-related data and their appropriate
           processing, the sponsor will apply quality control to each step of data handling

      Monitoring

        -  In order to confirm that the study is being conducted, recorded and reported according
           to the study protocol and International Conference on Harmonization Good Clinical
           Practice(ICH-GCP), the sponsor or CRO will perform monitoring of study procedure. In
           monitoring, the monitors will cross check the description in the case report form, etc.
           against study-related records such as source documents to confirm that the description
           is accurate.

      Measures taken to cope with adverse events and reporting procedure

        -  The investigator should notify the event to the sponsor or Contract Research
           Organization(CRO) immediately (within around 24 hours) after having noticed the
           occurence of a serioius adverse event by telephone, fax or E-mail. The investigator
           should complete and submit an serioius adverse event(SAE) report form containing all
           information to the Institutional Review Board (IRB).

      Data Management

        -  In this study, data will be collected in electronic Case Report Form(CRF)

        -  Data validation for missing data will be managed by computer programming and manual
           check.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of non-HDL cholesterol</measure>
    <time_frame>at screening and after 12 weeks</time_frame>
    <description>-change rate : [(12nd week non-High density lipoprotein - baseline non-High density lipoprotein) / baseline non-High density lipoprotein] * 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>levelresponse rate of non-HDL cholesterol level &lt; 130mg/dL</measure>
    <time_frame>at screening and after 12 weeks</time_frame>
    <description>-Response rate : (subjects who are at less than 130mg/dL of non-High density lipoprotein level / all subjects) * 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of TC,HDL-C,LDL-C,TG,Apo B/A1</measure>
    <time_frame>at screening and after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Glucose, HbA1c, HOMA-IR level</measure>
    <time_frame>at screening and after 12 weeks</time_frame>
    <description>HOMA-IR index = [fasting serum insulin(uU/mL) * fasting serum glucose(mmol/L)]/22.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of hs-CRP, adiponectin, resistin level</measure>
    <time_frame>at screening and after 12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>changes of BUN/Cr level</measure>
    <time_frame>at screening and after 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes of Homocysteine level</measure>
    <time_frame>at screening and after 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Mixed Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 20mg, monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 20mg/day PO for 12weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 10mg, Fenofibric acid 135mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 10mg, Fenofibric acid 135mg per day PO for 12weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10mg, fenofibric acid 135mg</intervention_name>
    <description>Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks</description>
    <arm_group_label>Atorvastatin 10mg, Fenofibric acid 135mg</arm_group_label>
    <other_name>Newvast 10mg, Fenocid 135mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin 20mg</intervention_name>
    <description>Atorvastatin 20mg/day PO for 12weeks</description>
    <arm_group_label>Atorvastatin 20mg, monotherapy</arm_group_label>
    <other_name>Newvast Tab. 20mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients of the age of 20years or older

          -  patients who have been taking atorvastatin 10mg 1 tab per day for more than 8 weeks
             before screening

          -  patients who meet the following criteria

               1. Low density lipoproteins-cholesterol level &lt; 130mg/dL

               2. 150mg/dL &lt; Triglyceride level &lt; 500mg/dL

               3. HDL-cholesterol level &lt; 45mg/dL

          -  patients who consent for the consent before enrolling the study

        Exclusion Criteria:

          -  Allergic to HMG-CoA reductase inhibitor and fibrates

          -  uncontrolled Hypertension

          -  unstable angina, myocardial infarction, transient ischemic attack

          -  uncontrolled diabetes

          -  thyroid disease

          -  myopathy, rhabdomyolysis history

          -  alcoholic

          -  chronic diarrhea, gastrointestinal disease

          -  malignant tumor

          -  patients who are pregnant

          -  lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Hak Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital, Yonsei University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Hak Lee, PhD</last_name>
      <phone>82-2-2228-8456</phone>
      <email>SHL1106@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Jiyeong Jeong, bachelor</last_name>
      <phone>82-2-2228-8277</phone>
      <email>jiyoung112@yuhs.ac</email>
    </contact_backup>
    <investigator>
      <last_name>Sang-Hak Lee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15;103(4):515-22. doi: 10.1016/j.amjcard.2008.10.025. Epub 2008 Dec 26.</citation>
    <PMID>19195513</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones PH, Goldberg AC, Knapp HR, Kelly MT, Setze CM, Stolzenbach JC, Sleep DJ. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J. 2010 Oct;160(4):759-66. doi: 10.1016/j.ahj.2010.06.045.</citation>
    <PMID>20934572</PMID>
  </results_reference>
  <results_reference>
    <citation>Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009 Jan;157(1):195-203. doi: 10.1016/j.ahj.2008.08.027. Epub 2008 Nov 20.</citation>
    <PMID>19081418</PMID>
  </results_reference>
  <results_reference>
    <citation>Kishikawa R, M-Horiuti T, Togawa A, Kondoh Y, Janzy PD, Goldblum RM, Kotoh E, Shimoda T, Shoji S, Nishima S, Brooks EG. [Juniper pollen monitoring by Burkard sampler in Galveston, Texas, USA and Japanese cedar pollen counting in Fukuoka, Japan -- introduction of Pan American Aerobiology Association protocol counting technique]. Arerugi. 2004 Jun;53(6):582-8. Japanese.</citation>
    <PMID>15247520</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009 May;204(1):208-15. doi: 10.1016/j.atherosclerosis.2008.09.027. Epub 2008 Oct 5.</citation>
    <PMID>18996523</PMID>
  </results_reference>
  <results_reference>
    <citation>Filippatos TD. A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovasc Drugs Ther. 2012 Jun;26(3):245-55. doi: 10.1007/s10557-012-6394-0. Review.</citation>
    <PMID>22592524</PMID>
  </results_reference>
  <results_reference>
    <citation>Chatley P, Badyal DK, Calton R, Khosla PP. Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia. Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):217-21.</citation>
    <PMID>17520105</PMID>
  </results_reference>
  <results_reference>
    <citation>Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.</citation>
    <PMID>20110022</PMID>
  </results_reference>
  <results_reference>
    <citation>Shah HD, Parikh KH, Chag MC, Shah UG, Baxi HA, Chandarana AH, Naik AM, Shah JN, Iyer S, Shah KJ, Goyal RK. Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. Exp Clin Cardiol. 2007 Summer;12(2):91-6.</citation>
    <PMID>18650989</PMID>
  </results_reference>
  <results_reference>
    <citation>Farnier M, Ducobu J, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. Am J Cardiol. 2010 Sep 15;106(6):787-92. doi: 10.1016/j.amjcard.2010.05.005. Epub 2010 Aug 2.</citation>
    <PMID>20816118</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Sang Hak Lee</investigator_full_name>
    <investigator_title>Associate Professor in Cardiology(preventive cardiology) in Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea</investigator_title>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Fenofibric acid</keyword>
  <keyword>combination</keyword>
  <keyword>monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type V</mesh_term>
    <mesh_term>Lipidoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Fenofibric acid</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

